RE
RXRX icon

RBC Europe’s Recursion Pharmaceuticals RXRX Stock Holding History

RBC Europe’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,340
Closed -$30.8K – 1044
2021
Q3 		$30.8K Buy
1,340
+500
+60% +$14.2K ﹤0.01% 683
2021
Q2 		$30.7K Buy
+840
New +$24.9K ﹤0.01% 706

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

RBC Europe's RXRX Position: Q4 2021 in Review

RBC Europe sold out of Recursion Pharmaceuticals (RXRX) in Q4 2021, closing a stake of 1,340 shares — an estimated $30.8K sold.

RBC Europe first reported a position in RXRX in Q2 2021 and held it in 2 quarters. The position peaked at $30.8K in Q3 2021. 126 funds tracked by Wall St. Rank hold RXRX as of Q4 2021.

  • RBC Europe reported no remaining Recursion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 1,340 Recursion Pharmaceuticals shares in Q4 2021, an estimated $30.8K.
  • RBC Europe first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • RBC Europe's Recursion Pharmaceuticals position peaked at $30.8K in Q3 2021.
  • 126 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.